Debt (Details) - USD ($) $ in Thousands		3 Months Ended
	Feb. 21, 2020	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Total long-term debt		$ 621,476
Long-term debt interest expense
Total debt interest expense		11,655	$ 11,873
Principal payment on notes			5,698
Issuer II Class C Units
Long-term debt interest expense
Percentage of equity interest	75.00%
9.5% Non-Recourse 2035 Notes
Debt Instrument [Line Items]
Principal amount	$ 400,000	418,251
Less: 5% retained by the Company		(20,913)
Unamortized debt issuance costs		(2,949)
Total long-term debt		$ 393,173
Long-term debt interest expense
Interest rate (as a percent)	9.50%	9.50%
Percentage of note to be sold	95.00%
Percentage of note to be retained	5.00%
Net principal		$ 397,300
Estimated fair value		377,500
9.0% Non-Recourse 2033 Notes
Debt Instrument [Line Items]
Unamortized debt issuance costs		(1,216)
Long-term debt interest expense
Total debt interest expense		$ 1,900	1,900
Interest rate (as a percent)		9.00%
3.25% Convertible Senior Notes Due 2023
Debt Instrument [Line Items]
Principal amount		$ 230,000
Unamortized debt issuance costs		(1,697)
Total long-term debt		228,303
Long-term debt interest expense
Amortization of debt issuance costs		$ 300	$ 300
Interest rate (as a percent)		3.25%
Notes fair value		$ 223,700
TRC
Long-term debt interest expense
Percentage of economic interest	85.00%
Net interest shortfall		$ 4,700
Percentage of equity interest		85.00%
Net interest shortfall		$ 28,000
Net principal paydown		$ 10,700
TRC | Minimum
Long-term debt interest expense
Upward tiering royalties (as a percent)	6.50%
TRC | Maximum
Long-term debt interest expense
Upward tiering royalties (as a percent)	10.00%
TRC | Issuer II Class C Units
Long-term debt interest expense
Percentage of economic interest	63.75%
Theravance Biopharma R&D, Inc. | 9.5% Non-Recourse 2035 Notes
Long-term debt interest expense
Interest rate (as a percent)		5.00%